Biotech Firm Adjusts Placement Terms to Fuel U.S. Expansion
Source: Streetwise Reports (07/07/2025)
Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out.
read more >
AI-Powered Medical Education Suite Cuts Costs, whilst Enhancing Clinical Skills Training for Future Doctors
Source: Streetwise Reports (06/16/2025)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launched its enhanced medical education suite in Minnesota, showing strong reliability and providing schools with up to 40% cost savings. Read on to find out how AI-simulated patients are reshaping medical education and enhancing clinical skills at scale.
read more >
Healthcare Firm Uncovers AI Healthcare Growth Opportunity
Source: Streetwise Reports (06/06/2025)
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.
read more >
Co. Poised to Begin Major New Bull Market
Source: Clive Maund (05/23/2025)
Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy.
read more >
Centrally Positioned AI Co. Platform Designed To Transform Healthcare
Source: Clive Maund (05/21/2025)
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA).
read more >